Hadron therapy Market Booming Worldwide Opportunity, Competitive Analysis, Future Prospects 2032

 By 2022, the Hadron therapy Market will be worth US$ 1,412.9 million, and by 2032, it will be worth US$ 4,812 million. The market is anticipated to grow at a CAGR of 11.8% from 2022 to 2032, down from 17.1% from 2016 to 21. Throughout the forecast period, it is anticipated that the rising incidence of cancer will be the main factor driving the global market for hadron therapy.

The main distinction between hadron therapy and other forms of radiation therapy is that the radiation beams used in hadron therapy are made up of charged particles (protons and other ions, such as carbon).

The physical and radiobiological characteristics of the particles, which enable them to penetrate the tissues with minimum diffusion and transfer maximal energy within a localised area, are the distinctive feature of hadron therapy. Hadron therapy, an essential component of radiation therapy for paediatric patients and tumours near crucial body structures, causes less damage to the healthy tissues surrounding the malignant region than X-rays.

Request Sample Report: https://www.futuremarketinsights.com/reports/sample/rep-gb-4052

The European Network for Light Ion Hadron Treatment reports that over 120,000 patients have received hadron therapy worldwide, 20,000 of whom received carbon ions. The cost of a single cycle of hadron therapy treatment in the US is estimated by Tata Memorial Centre to be between USD 150,000 and USD 200,000.

Hadron Therapy Market: Drivers and Restraints

The key contributor to the growth of global hadron therapy market is increasing number of people diagnosed with cancer worldwide.

Technological advancements such as reduced adverse effects and less radiation dose transferred to healthy tissues during the radiation procedure have attracted the attention of healthcare professionals and patients as well.

However, very few number of therapy providers, high cost of the treatment, large area required for the installation of equipment, space for optimization and refinement of technology and lack of skilled clinicians may restrict the growth of the market.

Hadron Therapy Market: Overview

Global hadron therapy market is highly consolidated with a very few number of players. According to Tata Memorial Centre, around 10-15% of patients receiving radiation therapy would get benefit from hadron therapy across the globe.

The cost of therapy is very high, which makes it inaccessible from most of the population. Most of the treatment providers are government hospitals or government-aided centers/universities.

The equipments are too costly that small clinics cannot purchase them. Installation of the equipment adds to the cost as it requires a large space.

However, the market of hadron therapy will grow owing to prevalence of a huge population pool living with cancer.

Hadron Therapy Market: Region-wise Outlook

Geographically, Hadron Therapy Market  is segmented into regions viz. North America, Latin America, Western Europe, Eastern Europe, Asia-Pacific excluding Japan, Japan, Middle East and Africa.

Developed markets like North America is currently the leader of the market followed by Europe. Most of the treatment providers are present in North America and Europe only.

However, Japan & Korea also have few facilities of therapy. India and China are also able to provide the therapy to the patients with very few service providers. It is expected that there will be around 100 hadron therapy centres across the globe by 2020, around 30% of them in Europe only.

Hadron Therapy Market: Key Players

The key players in the global Hadron Therapy Market include IBA Worldwide, Koninklijke Philips N.V., Advanced Oncotherapy, Optivus Proton Therapy, Inc., Varian Medical Systems, Inc., Hitachi, Ltd., Mevion Medical Systems, Sumitomo Corporation, ProNova Solutions, LLC, Mitsubishi Electric Corporation, ProTom International and Elekta.

The research report presents a comprehensive assessment of the market and contains thoughtful insights, facts, historical data, and statistically supported and industry-validated market data.

It also contains projections using a suitable set of assumptions and methodologies.

The research report provides analysis and information according to categories such as market segments, geographies, types, technology and applications.

Regional analysis includes

• North America (U.S., Canada)
• Latin America (Mexico, Brazil and Rest of Latin America)
• Western Europe (Germany, Italy, France, U.K, Spain, Nordic countries, Belgium, Netherlands, Luxembourg and Rest of Western Europe)
• Eastern Europe (Poland, Russia and Rest of Eastern Europe)
• Asia Pacific (China, India, ASEAN, Australia & New Zealand)
• Japan
• Middle East and Africa (GCC, S. Africa, and Rest of MEA)

The report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain.

The report provides in-depth analysis of parent market trends, macro-economic indicators and governing factors along with market attractiveness as per segments.

The report also maps the qualitative impact of various market factors on market segments and geographies.

Hadron Therapy Market: Segmentation

Global Hadron Therapy Market has been segmented on the basis of type of particle radiation, application, end user and region.

Based on the type of particle radiation, the global Hadron Therapy Market is segmented into:

• Electron Beam
• Proton Beam
• Neutron Beam
• Carbon Ion Beam
• Alpha Particle Beam
• Beta Particle Beam

Based on the application, the global Hadron Therapy Market is segmented into:

• Pediatric Cancer
• Bone & Soft Tissue Cancer
• Prostate Cancer
• Lung Cancer
• Liver Cancer
• Eye Cancer
• Head & Neck Cancer

Based on the end user, the global Hadron Therapy Market is segmented into the following:

• Hospitals
• Government Universities
• Research Institutions